All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | == Further reading == * {{cite journal | vauthors = Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C | display-authors = 6 | title = Telmisartan, ramipril, or both in patients at high risk for vascular events | journal = The New England Journal of Medicine | volume = 358 | issue = 15 | pages = 1547–59 | date = April 2008 | pmid = 18378520 | doi = 10.1056/nejmoa0801317 | publisher = Massachusetts Medical Society | hdl = 2437/81925 | hdl-access = free }} * {{cite journal | vauthors = Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P | display-authors = 6 | title = Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | journal = Lancet | volume = 372 | issue = 9644 | pages = 1174–83 | date = September 2008 | pmid = 18757085 | doi = 10.1016/S0140-6736(08)61242-8 | s2cid = 5203511 | url = https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61242-8/abstract | access-date = 26 November 2019 }} |
| h Japanese (ja) | == さらに読む == * {{cite journal | vauthors = Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C | display-authors = 6 | title = Telmisartan, ramipril, or both in patients at high risk for vascular events | journal = The New England Journal of Medicine | volume = 358 | issue = 15 | pages = 1547–59 | date = April 2008 | pmid = 18378520 | doi = 10.1056/nejmoa0801317 | publisher = Massachusetts Medical Society | hdl = 2437/81925 | hdl-access = free }} * {{cite journal | vauthors = Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P | display-authors = 6 | title = Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | journal = Lancet | volume = 372 | issue = 9644 | pages = 1174–83 | date = September 2008 | pmid = 18757085 | doi = 10.1016/S0140-6736(08)61242-8 | s2cid = 5203511 | url = https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61242-8/abstract | access-date = 26 November 2019 }} |